How artificial intelligence is improving the accuracy of melanoma diagnosis from dermoscopy
Australia has one of the world’s highest rates of melanoma, making earlier and more reliable diagnosis a major public health priority. Dermoscopy gives clinicians a magnified view of pigmented lesions, revealing colours and structures that may be difficult to see with the naked eye. Artificial intelligence is now adding another layer of analysis by identifying visual patterns associated with melanoma and other skin cancers.
This technology is designed to support, rather than replace, dermatologists, general practitioners and skin cancer clinicians. When carefully validated and integrated into clinical practice, machine learning can help prioritise suspicious lesions, reduce missed melanomas and make specialist expertise more accessible across metropolitan, regional and remote communities.
How AI reads dermoscopic images
AI systems trained on large collections of dermoscopic photographs learn to recognise features linked with malignancy. These may include irregular pigment networks, asymmetry, multiple colours, atypical dots and globules, blue-white structures, and changes in lesion architecture. A trained algorithm can compare a new image with thousands of previously labelled examples within seconds.
The most effective systems use deep learning, particularly convolutional neural networks, to analyse patterns that are difficult to define through simple rules. The software may produce a probability score, classify a lesion as suspicious, or highlight areas that warrant closer review. This can support a clinician’s assessment alongside the patient’s history, physical examination and previous images.
Accuracy depends on the quality and diversity of the training data. An algorithm exposed to images from only one clinic, camera or patient group may perform less reliably in other settings. Validation across different skin types, ages, devices and clinical environments is therefore essential before a tool is used widely in Australian healthcare.
Earlier detection through clinical decision support
A key benefit of computer-assisted diagnosis is improved triage. In a busy general practice in Brisbane, for example, an AI-enabled dermoscopy platform may help a GP identify which lesions require urgent dermatology referral, biopsy or specialist telehealth review. This can be particularly valuable when a patient has multiple naevi or when a suspicious mark looks subtle.
AI may also improve consistency between clinicians. Human assessment can vary with experience, fatigue, image quality and the visual complexity of a lesion. A decision-support tool provides a second assessment that can prompt a closer examination rather than allowing an easily overlooked melanoma to pass unnoticed.
Used appropriately, these systems can help manage growing demand for skin checks. Australia’s mobile and outdoor lifestyles, sun exposure in Queensland, and long travel distances for some rural patients create practical pressure on skin cancer services. Digital imaging and remote review may help connect people in regional Queensland with specialist advice without requiring every patient to travel to Brisbane.
Supporting clinicians without removing judgement
An AI result is not a diagnosis by itself. A lesion’s appearance must be considered alongside its growth pattern, location, patient history, family risk, previous skin cancers and symptoms such as bleeding or persistent change. If the clinical picture conflicts with the algorithm, the clinician must be able to investigate further or arrange a biopsy.
Good software should explain its output in a clinically useful way. Heat maps, highlighted image regions or comparable reference cases can show why a lesion was flagged, although these explanations must be interpreted carefully. A high-risk score should encourage review, not create automatic certainty, while a low-risk score should never override strong clinical concern.
This is where health translation partnerships matter. Organisations such as Brisbane Diamantina Health Partners bring researchers, universities and health services together to assess whether innovations work in real care settings. For melanoma diagnosis, that means moving beyond impressive laboratory results and measuring effects on referrals, biopsy decisions, waiting times and patient outcomes.
Building trustworthy tools for Australian care
Before implementation, AI tools need rigorous testing on representative Australian data. The local population includes people with a wide range of skin tones, genetic backgrounds and patterns of sun exposure. A model developed mainly from European datasets may not perform equally well for Aboriginal and Torres Strait Islander people or for patients with darker skin, where melanoma can present differently and may occur in less sun-exposed areas.
Privacy and consent also require careful attention. Dermoscopic photographs are health information, and images used for training or research need appropriate governance, secure storage and clear rules about secondary use. Patients should understand whether an image is being used only for their care or also to improve an algorithm.
Health services should monitor performance after deployment rather than treating approval as the end of evaluation. Useful measures include sensitivity, specificity, false-positive referrals, missed cancers, biopsy rates and differences in outcomes between population groups. Strong governance helps ensure that speed and automation do not weaken informed consent or clinical accountability.
What patients and practices can expect
For patients, AI-supported dermoscopy may mean a more structured skin examination and faster escalation of concerning lesions. It may also make serial imaging more useful by comparing photographs over time and identifying subtle changes. However, regular checks remain important because no software can identify every melanoma, and a new or changing lesion should be assessed promptly.
For practices, implementation involves more than purchasing a camera or subscribing to an application. Staff need training in image capture, referral pathways, data security and communication with patients. The system must fit existing clinical records and avoid creating extra administrative work that reduces the time available for care.
Practical features worth assessing include:
- Validation on Australian patient images and multiple skin types
- Clear integration with clinical records and referral systems
- Human review for high-risk or uncertain results
- Transparent privacy, consent and data-retention policies
Patients can also benefit when clinicians explain the limits of automated analysis. A reassuring result should support ongoing surveillance rather than end it, while a concerning result should be discussed in plain language with a clear next step.
Important questions for health services include:
- How is accuracy monitored after rollout?
- Who reviews algorithmic errors or disputed results?
- Can rural and regional patients access the same standard of assessment?
- Is the tool improving outcomes rather than simply increasing referrals?
Translating promising research into better outcomes
The strongest future for AI in melanoma care is collaborative. Researchers can improve algorithms, clinicians can test workflow and safety, patients can shape consent and communication standards, and health services can measure whether the technology delivers meaningful benefits. Clinical innovation should be judged by better diagnosis and care, not by technical sophistication alone.
Dermoscopy remains central because it captures clinically valuable detail, while artificial intelligence adds pattern recognition and consistency. Together, they may help clinicians detect melanoma earlier, reduce variation in assessment and direct specialist resources to patients who need them most. Continued research, ethical oversight and transparent evaluation will determine how safely these benefits are realised across Australia.
Health professionals, researchers and service leaders can support this progress by connecting with Queensland’s health research and translation community, contributing high-quality local evidence and adopting validated tools with appropriate safeguards. Through coordinated action, AI-assisted melanoma assessment can become a practical part of safer, more timely skin cancer care.
